Danaher Co. (NYSE:DHR) Stock Holdings Increased by Schubert & Co

Schubert & Co boosted its stake in Danaher Co. (NYSE:DHR) by 1,532.8% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 39,530 shares of the conglomerate’s stock after buying an additional 37,109 shares during the period. Danaher makes up approximately 6.1% of Schubert & Co’s portfolio, making the stock its 4th biggest position. Schubert & Co’s holdings in Danaher were worth $9,074,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently bought and sold shares of DHR. Kovack Advisors Inc. grew its position in Danaher by 3.4% in the 3rd quarter. Kovack Advisors Inc. now owns 1,243 shares of the conglomerate’s stock valued at $346,000 after buying an additional 41 shares during the last quarter. Gilbert & Cook Inc. lifted its holdings in Danaher by 2.5% in the fourth quarter. Gilbert & Cook Inc. now owns 1,749 shares of the conglomerate’s stock valued at $401,000 after acquiring an additional 42 shares during the period. Grimes & Company Inc. lifted its holdings in Danaher by 0.6% in the fourth quarter. Grimes & Company Inc. now owns 7,390 shares of the conglomerate’s stock valued at $1,696,000 after acquiring an additional 43 shares during the period. Harbour Investments Inc. lifted its holdings in Danaher by 3.0% in the third quarter. Harbour Investments Inc. now owns 1,531 shares of the conglomerate’s stock valued at $426,000 after acquiring an additional 45 shares during the period. Finally, Dakota Community Bank & Trust NA lifted its holdings in Danaher by 16.4% in the fourth quarter. Dakota Community Bank & Trust NA now owns 320 shares of the conglomerate’s stock valued at $73,000 after acquiring an additional 45 shares during the period. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Danaher Trading Up 1.5 %

Shares of DHR stock opened at $206.66 on Tuesday. The firm has a 50-day moving average price of $229.53 and a 200 day moving average price of $249.13. Danaher Co. has a twelve month low of $196.80 and a twelve month high of $281.70. The company has a market capitalization of $149.26 billion, a price-to-earnings ratio of 39.14, a PEG ratio of 2.68 and a beta of 0.83. The company has a current ratio of 1.40, a quick ratio of 1.05 and a debt-to-equity ratio of 0.31.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Wednesday, January 29th. The conglomerate reported $2.14 EPS for the quarter, meeting the consensus estimate of $2.14. Danaher had a return on equity of 10.82% and a net margin of 16.33%. During the same period in the previous year, the business posted $2.09 earnings per share. Research analysts forecast that Danaher Co. will post 7.67 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, January 31st. Shareholders of record on Friday, December 27th were issued a $0.27 dividend. This represents a $1.08 annualized dividend and a yield of 0.52%. The ex-dividend date was Friday, December 27th. Danaher’s dividend payout ratio (DPR) is 20.45%.

Insider Buying and Selling at Danaher

In other news, SVP Brian W. Ellis sold 5,700 shares of the business’s stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $224.13, for a total transaction of $1,277,541.00. Following the completion of the sale, the senior vice president now owns 20,230 shares in the company, valued at approximately $4,534,149.90. The trade was a 21.98 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 11.10% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the company. TD Cowen raised their target price on Danaher from $310.00 to $315.00 and gave the company a “buy” rating in a report on Wednesday, October 23rd. Guggenheim assumed coverage on Danaher in a report on Thursday, December 19th. They issued a “buy” rating and a $275.00 target price for the company. Robert W. Baird reduced their target price on Danaher from $277.00 to $268.00 and set an “overweight” rating for the company in a report on Tuesday, January 28th. Stifel Nicolaus raised their target price on Danaher from $250.00 to $265.00 and gave the company a “hold” rating in a report on Wednesday, October 23rd. Finally, StockNews.com downgraded Danaher from a “buy” rating to a “hold” rating in a research note on Saturday, December 14th. Seven analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. According to MarketBeat, Danaher presently has an average rating of “Moderate Buy” and an average target price of $278.00.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.